RNAi News incorrectly reported last week that Cenix Bioscience has signed a deal with Schering expanding upon existing large-scale target screening projects. In fact,the arrangement is the companies’ first, and involves Cenix performing target validation for Schering, not target screening work.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.